Home - AME Clinical Trials Review

Reviewer of the Month (2025)

In 2025, ACTR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Interviews with Outstanding Authors (2025)

In 2025, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

ACTR Annual Report 2024

Greetings from the Editorial Office of AME Clinical Trials Review (ACTR).

We are glad to present the 2024 Annual Report of ACTR, which has shown the author statistics, pageviews and visits of ACTR articles, as well as previews of upcoming reviews and commentaries in the coming year.

Prediction of lymphatic invasion for patients with early gastric cancer: a review

Elfriede Bollschweiler, Patrick S. Plum
Review Article｜25 August 2024
doi: 10.21037/actr-24-33

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

I am excited to announce the launch of AME Clinical Trials Review (ACTR), an open-access, peer-reviewed journal publishing commentaries on clinical trials in all phases.

Why launch ACTR? Tens of thousands of clinical trials are published every year, and the total number of published clinical trials in PubMed is nearly a million, with an additional 80,000 recruiting and not-yet-recruiting studies registered in the ClinicalTrials.gov platform.

Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review

Eric M. Robinson, Raja Flores, Brian Housman
Review Article｜25 December 2024
doi: 10.21037/actr-24-149

‹ ›

Cover image "A Picture in a Picture" by Dr. Anthony P Yim, MD More >>

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: actr@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial Commentary

Treatment of newly diagnosed transplant ineligible multiple myeloma: is there a BENEFIT to adding bortezomib to the standard backbone?

Issam S. Hamadeh, Barry Paul

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (7) Peer Review File COI Form Open Access

Editorial Commentary

COSMIC-312: lessons learned from another combination immune checkpoint and multi-kinase inhibitor trial

Joycelyn J. X. Lee, Suat Ying Lee, David Tai, Su Pin Choo

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (8) Peer Review File COI Form Open Access

Editorial Commentary

Nutrition following esophagectomy, what’s best?

Anna van Herwijnen, Misha D. Luyer

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (10) Peer Review File COI Form Open Access

Editorial Commentary

The new kid on the block: will asciminib change frontline therapy of chronic myeloid leukemia patients?

Mario Tiribelli, Gianni Binotto, Massimiliano Bonifacio

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (7) Peer Review File COI Form Open Access

Editorial Commentary

Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer

Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Fabrício Freire de Melo

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (7) Peer Review File COI Form Open Access

Editorial Commentary

Lung cancer detection by electronic nose: ready for prime time?

Alessandra I. G. Buma, Michel M. van den Heuvel

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (6) Peer Review File COI Form Open Access

Editorial Commentary

Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients

Klaus Podar

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (10) Peer Review File COI Form Open Access

Editorial Commentary

Immunotherapy as the new standard of care for advanced endometrial cancer

Giovanna Vieira Giannecchini, Martina Parenza Arenhardt, Andreia Cristina de Melo

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (7) Peer Review File COI Form Open Access

Editorial Commentary

Should routine dual antiplatelet therapy be recommended after elective coronary artery bypass surgery: insights from the DACAB-FE trial

Richard Z. Lin, Jessica A. Marathe, Peter J. Psaltis, Adam J. Nelson

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (7) Peer Review File COI Form Open Access

Editorial Commentary

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial: the additive value of radiation therapy in the management of patients with lymphoma

Thomas J. FitzGerald

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (10) Peer Review File COI Form Open Access

Review Article

Is it time to recommend dual antiplatelet therapy for all following coronary artery bypass graft surgery?—an updated review of clinical trials

Rushmi Purmessur, Zeba Ahmed, Jason Ali

AME Clinical Trials Review

2025;

(25 June 2025)

PDF Full Text (10) Peer Review File COI Form Open Access

Editorial Commentary

Lessons from FOWARC: moving towards the more precise use of radiation therapy in the era of total neoadjuvant therapy

Aron Bercz, Wini Zambare, J. Joshua Smith

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (309) Peer Review File COI Form Open Access

Editorial Commentary

Stereotactic ablative radiotherapy as a novel strategy in patients with oligometastatic hepatocellular carcinoma

Tomoki Kimura, Toshiki Fujiwara, Taro Ueda, Takuya Ogura, Shinji Kariya

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (165) Peer Review File COI Form Open Access

Editorial Commentary

Finding the RIGHT Choice in patients with clinically aggressive ER-positive HER2-negative metastatic breast cancer

Maiane Maria Pauletto, Tomás Reinert

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (278) Peer Review File COI Form Open Access

Editorial Commentary

Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression

Maria Aguado Sorolla, Sergio Martínez-Recio, Andrés Barba Joaquin, Mikel Portu Grivé, Margarita Majem Tarruella

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (197) Peer Review File COI Form Open Access

Editorial Commentary

Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer

Claudia Parisi, David Planchard, Fabrice Barlesi

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (424) Peer Review File COI Form Open Access

Editorial Commentary

Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC

Christian Huisman, Pim Rozendal, Ed Schuuring, T. Jeroen N. Hiltermann

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (448) Peer Review File COI Form Open Access

Editorial Commentary

Revumenib: a new potential targeted therapy for KMT2A-rearranged acute leukemia

Xavier Thomas

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (265) Peer Review File COI Form Open Access

Editorial Commentary

Intravascular imaging guided optimization in complex percutaneous coronary intervention (PCI)—does clinical presentation matter?

Vishal Goel, Nitesh Nerlekar, Adam J. Brown

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (155) Peer Review File COI Form Open Access

Editorial Commentary

Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

John M. Flack

AME Clinical Trials Review

2025;

(25 April 2025)

PDF Full Text (798) Peer Review File COI Form Open Access

View more articles

Editorial Commentary

Exploring the role of triplet therapy in relapsed chronic lymphocytic leukemia (CLL) and an emerging role for ctDNA in CLL: key takeaways from the CLL2-BAAG trial

Meghan C. Thompson

Published online: 16 May 2025

Editorial Commentary

Advancing HER2-positive breast cancer treatment: the promise and challenges of trastuzumab deruxtecan over trastuzumab emtansine—DESTINY-Breast03 trial

Suguru Ogata, Yee Chung Cheng, Naoto T. Ueno

Published online: 16 May 2025

Editorial Commentary

Sex-specific approach to only optimize acetylsalicylic acid dosing for secondary prevention in cardiovascular disease is definitely questionable—insights from the ADAPTABLE trial and beyond

Davide Santagata, Alessandro Squizzato

Published online: 15 May 2025

Editorial Commentary

Dual attack on multiple myeloma: targeting BCMA and CD19

Naresh Bumma, Srinivas Devarakonda, Abdullah Khan

Published online: 14 May 2025

Editorial Commentary

Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management

Wini Zambare, Aron Bercz, J. Joshua Smith

Published online: 13 May 2025

Editorial Commentary

Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: light and gloom

Debora Basile, Vittoria Piva, Giulia Barsotti, Giuseppe Aprile

Published online: 08 May 2025

Editorial Commentary

Is there a role for triple chemotherapy in advanced biliary tract cancer?

Virginia Genovesi, Francesca Salani, Caterina Vivaldi, Silvia Cesario, Lorenzo Fornaro, Gianluca Masi

Published online: 07 May 2025

Editorial Commentary

The UNION trial: open the door to immune checkpoint inhibitors for proficient mismatch repair/microsatellite stability rectal cancer?

Yoshinori Kagawa, Jun Watanabe, Koji Ando

Published online: 07 May 2025

Editorial Commentary

The central nervous system protective activity of selpercatinib from LIBRETTO-431

Joe Q. Wei, Alexander Yuile, Aaron C. Tan

Published online: 07 May 2025

Editorial Commentary

Cabozantinib: a promising advancement in the treatment of advanced neuroendocrine tumors

Francesco Panzuto, Giulia Arrivi, Matteo Marasco, Maria Rinzivillo

Published online: 07 May 2025

Editorial Commentary

Abiraterone + olaparib in metastatic castration-resistant prostate cancer: tolerable, not toxic

Sarah Williams, Louise Kostos, Arun A. Azad

Published online: 07 May 2025

Editorial Commentary

The CLL2-BAAG trial provides further evidence supporting a minimal residual disease driven approach and triple therapy in relapsed chronic lymphocytic leukaemia

Abraham Mullasseril Varghese, Talha Munir

Published online: 07 May 2025

Editorial Commentary

Balancing treatment efficacy and complications in early-onset locally advanced rectal cancer

Francesca Negri, Carlo Aschele

Published online: 29 April 2025

Editorial Commentary

Early implementation of exercise after breast cancer surgery: insights and opportunity

Valeria Masiello, Fabio Marazzi

Published online: 29 April 2025

Editorial Commentary

Transforming post-surgical lung cancer recovery: app-based approach to telerehabilitation

Rogih Riad Andrawes, Dmitry Rozenberg

Published online: 22 April 2025

Editorial Commentary

Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu

Published online: 15 August 2024

PDF Full Text (3886) Peer Review File COI Form Open Access

Editorial Commentary

KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction

Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo

Published online: 11 June 2024

PDF Full Text (3543) Peer Review File COI Form Open Access

Editorial Commentary

What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?

Toyoaki Hida

Published online: 20 October 2023

PDF Full Text (3226) Peer Review File COI Form Open Access

Editorial Commentary

The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer

Antonio Rossi, Ettore Mari, Domenico Galetta

Published online: 06 September 2023

PDF Full Text (2957) Peer Review File COI Form Open Access

Editorial Commentary

The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)

Yuji Uehara, Aaron C. Tan

Published online: 06 June 2024

PDF Full Text (2805) Peer Review File COI Form Open Access

Editorial Commentary

Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?

Daniela Damiani, Mario Tiribelli

Published online: 20 June 2024

PDF Full Text (1724) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial

Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group

Published online: 20 December 2024

PDF Full Text (1650) Peer Review File COI Form Open Access

Editorial Commentary

ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma

Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona

Published online: 09 April 2024

PDF Full Text (1637) Peer Review File COI Form Open Access

Editorial Commentary

Targeting TIGIT in lung cancer: will it stick to the wall?

Jiaxin Niu, Saba Radhi

Published online: 21 June 2024

PDF Full Text (1476) Peer Review File COI Form Open Access

Editorial Commentary

Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

Anuja Abhyankar, Grace K. Dy

Published online: 21 August 2024

PDF Full Text (1390) Peer Review File COI Form Open Access

Editorial Commentary

Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri

Published online: 09 April 2024

PDF Full Text (1344) Peer Review File COI Form Open Access

Editorial Commentary

Hyperthermic intraperitoneal chemotherapy in colorectal cancer: is COLOPEC just another brick in the wall?

Beate Rau, Sebastian Stintzing

Published online: 18 June 2024

PDF Full Text (1255) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma

Shinji Yuhara, Yoshihisa Shimada, Masaaki Sato

Published online: 27 March 2024

PDF Full Text (1283) Peer Review File COI Form Open Access

Editorial Commentary

The future of EGFR exon 20 targeting in non-small cell lung cancer

Petros Christopoulos

Published online: 13 June 2024

PDF Full Text (1256) Peer Review File COI Form Open Access

Editorial Commentary

Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?

Yu Saida, Satoshi Watanabe, Toshiaki Kikuchi

Published online: 17 June 2024

PDF Full Text (1207) Peer Review File COI Form Open Access

Editorial Commentary

A new ALK inhibitor is not a game changer, but an older one is!

Beatriz Jimenez Munarriz, Geoffrey Liu, Sam Khan

Published online: 12 October 2024

PDF Full Text (1108) Peer Review File COI Form Open Access

Editorial Commentary

EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges

Mingjia Li, Dwight H. Owen, Gregory A. Otterson

Published online: 18 December 2023

PDF Full Text (1049) Peer Review File COI Form Open Access

Editorial Commentary

The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial

Saurav Verma, Jacques Raphael

Published online: 02 September 2024

PDF Full Text (1029) Peer Review File COI Form Open Access

Editorial Commentary

YK-029A in the landscape of treatments for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations

Margaret Locke, Wint Yan Aung, Nagashree Seetharamu

Published online: 20 June 2024

PDF Full Text (1060) Peer Review File COI Form Open Access

Editorial Commentary

Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer

Lauren Tagliaferro Epler, Joel W. Neal

Published online: 29 January 2024

PDF Full Text (1097) Peer Review File COI Form Open Access

Full Most Read article list >>

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>